astellas pharma ltd.

3.5

astellas pharma ltd. Company Information

Share ASTELLAS PHARMA LTD.
Live 
MatureMegaLow

Company Number

00787610

Registered Address

300 dashwood lang road, bourne business park, addlestone, KT15 2NX

Industry

Wholesale of pharmaceutical goods

 

Telephone

02033798700

Next Accounts Due

December 2024

Group Structure

View All

Directors

Jacqueline Davis3 Years

Rowena Borenstein2 Years

View All

Shareholders

astellas pharma europe ltd 100%

astellas pharma ltd. Estimated Valuation

£119m

Pomanda estimates the enterprise value of ASTELLAS PHARMA LTD. at £119m based on a Turnover of £172.5m and 0.69x industry multiple (adjusted for size and gross margin).

astellas pharma ltd. Estimated Valuation

£44.7m

Pomanda estimates the enterprise value of ASTELLAS PHARMA LTD. at £44.7m based on an EBITDA of £7.2m and a 6.17x industry multiple (adjusted for size and gross margin).

astellas pharma ltd. Estimated Valuation

£159.6m

Pomanda estimates the enterprise value of ASTELLAS PHARMA LTD. at £159.6m based on Net Assets of £76.8m and 2.08x industry multiple (adjusted for liquidity).

Valuation Calculator
This valuation is estimated based on financial data from March 2023 

Astellas Pharma Ltd. AI Business Plan

In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.

View Sample

Astellas Pharma Ltd. Overview

Astellas Pharma Ltd. is a live company located in addlestone, KT15 2NX with a Companies House number of 00787610. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in January 1964, it's largest shareholder is astellas pharma europe ltd with a 100% stake. Astellas Pharma Ltd. is a mature, mega sized company, Pomanda has estimated its turnover at £172.5m with low growth in recent years.

View Sample
View Sample
View Sample

Upgrade for unlimited company reports & a free credit check

Astellas Pharma Ltd. Health Check

Pomanda's financial health check has awarded Astellas Pharma Ltd. a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs

Health Check Image
Health Rating3.5out of 5
positive_score

3 Strong

positive_score

3 Regular

positive_score

5 Weak

size

Size

annual sales of £172.5m, make it larger than the average company (£25.2m)

£172.5m - Astellas Pharma Ltd.

£25.2m - Industry AVG

growth

Growth

3 year (CAGR) sales growth of 2%, show it is growing at a slower rate (4.9%)

2% - Astellas Pharma Ltd.

4.9% - Industry AVG

production

Production

with a gross margin of 5%, this company has a higher cost of product (23.8%)

5% - Astellas Pharma Ltd.

23.8% - Industry AVG

profitability

Profitability

an operating margin of 3.8% make it as profitable than the average company (3.7%)

3.8% - Astellas Pharma Ltd.

3.7% - Industry AVG

employees

Employees

with 113 employees, this is above the industry average (37)

113 - Astellas Pharma Ltd.

37 - Industry AVG

paystructure

Pay Structure

on an average salary of £109k, the company has a higher pay structure (£66.5k)

£109k - Astellas Pharma Ltd.

£66.5k - Industry AVG

efficiency

Efficiency

resulting in sales per employee of £1.5m, this is more efficient (£631.6k)

£1.5m - Astellas Pharma Ltd.

£631.6k - Industry AVG

debtordays

Debtor Days

it gets paid by customers after 68 days, this is near the average (63 days)

68 days - Astellas Pharma Ltd.

63 days - Industry AVG

creditordays

Creditor Days

its suppliers are paid after 0 days, this is quicker than average (33 days)

0 days - Astellas Pharma Ltd.

33 days - Industry AVG

stockdays

Stock Days

it holds stock equivalent to 122 days, this is more than average (59 days)

122 days - Astellas Pharma Ltd.

59 days - Industry AVG

cashbalance

Cash Balance

There is insufficient data available for this Key Performance Indicator!

- - Astellas Pharma Ltd.

- - Industry AVG

debtlevel

Debt Level

it has a ratio of liabilities to total assets of 55.4%, this is a similar level of debt than the average (56.8%)

55.4% - Astellas Pharma Ltd.

56.8% - Industry AVG

astellas pharma ltd. Credit Report and Business Information

Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for astellas pharma ltd.. Get real-time insights into astellas pharma ltd.'s credit score, group structure and payment trends.

From as little as £6.99

This will not impact your credit rating!

View Credit Report Sample

Astellas Pharma Ltd. Competitor Analysis

BETA
competitor_analysis_table_img

Perform a competitor analysis for astellas pharma ltd. by selecting its closest rivals and benchmarking them against 12 key performance metrics.

astellas pharma ltd. Ownership

ASTELLAS PHARMA LTD. group structure

Astellas Pharma Ltd. has 1 subsidiary company.

Ultimate parent company

ASTELLAS PHARMA INC

#0017018

2 parents

ASTELLAS PHARMA LTD.

00787610

1 subsidiary

ASTELLAS PHARMA LTD. Shareholders

astellas pharma europe ltd 100%

astellas pharma ltd. directors

Astellas Pharma Ltd. currently has 4 directors. The longest serving directors include Mrs Jacqueline Davis (Apr 2020) and Ms Rowena Borenstein (Apr 2021).

officercountryagestartendrole
Mrs Jacqueline DavisUnited Kingdom54 years Apr 2020- Director
Ms Rowena BorensteinUnited Kingdom53 years Apr 2021- Director
Dr Martin ReadUnited Kingdom50 years Apr 2021- Director
Mr Yagnaram SantharamUnited Kingdom44 years Sep 2022- Director

ASTELLAS PHARMA LTD. financials

EXPORTms excel logo

Astellas Pharma Ltd.'s latest turnover from March 2023 is £172.5 million and the company has net assets of £76.8 million. According to their latest financial statements, Astellas Pharma Ltd. has 113 employees and maintains cash reserves of 0 as reported in the balance sheet.

Data source: Companies HousePomanda Estimates

Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Turnover172,509,000176,443,000169,933,000161,349,000188,837,000190,928,000196,115,000193,211,000176,911,000165,809,000140,534,000142,971,000132,427,000132,007,000
Other Income Or Grants00000000000000
Cost Of Sales163,942,000164,712,000140,546,000127,760,000154,306,000156,668,000146,868,000137,980,000126,122,000108,399,00090,885,00093,067,00086,236,00084,372,000
Gross Profit8,567,00011,731,00029,387,00033,589,00034,531,00034,260,00049,247,00055,231,00050,789,00057,410,00049,649,00049,904,00046,191,00047,635,000
Admin Expenses1,936,0003,827,00023,666,00026,391,00028,050,00028,164,00040,459,00049,292,00044,121,00051,589,00044,682,00044,911,00042,090,00042,864,000
Operating Profit6,631,0007,904,0005,721,0007,198,0006,481,0006,096,0008,788,0005,939,0006,668,0005,821,0004,967,0004,993,0004,101,0004,771,000
Interest Payable0022,000425,000632,000439,0003,000308,000199,000228,00096,000752,000685,000536,000
Interest Receivable756,00000335,000462,00036,00014,00029,00020,00019,0000568,000511,000444,000
Pre-Tax Profit7,343,0007,831,0005,576,0007,108,0006,311,0006,032,0008,709,0005,577,0006,445,0005,569,0004,824,0004,809,0003,927,0004,679,000
Tax-1,673,000-1,839,000-2,441,000-1,450,000-1,224,000-1,153,000-1,924,000-1,328,000-1,506,000-905,000-1,378,000-1,797,000-868,000-1,925,000
Profit After Tax5,670,0005,992,0003,135,0005,658,0005,087,0004,879,0006,785,0004,249,0004,939,0004,664,0003,446,0003,012,0003,059,0002,754,000
Dividends Paid00000000000000
Retained Profit5,670,0005,992,0003,135,0005,658,0005,087,0004,879,0006,785,0004,249,0004,939,0004,664,0003,446,0003,012,0003,059,0002,754,000
Employee Costs12,314,00012,082,00014,248,00014,511,00015,454,00018,151,00017,887,00018,249,00017,548,00016,229,00016,608,00017,112,00016,090,00014,698,000
Number Of Employees113120135144160195234236220221266279270250
EBITDA*7,246,0008,736,0006,602,0007,744,0006,516,0006,160,0008,852,0005,998,0007,390,0006,544,0005,752,0006,231,0004,835,0005,454,000

* Earnings Before Interest, Tax, Depreciation and Amortisation

Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Tangible Assets524,0004,344,0004,630,0005,433,000035,00099,000163,00029,00071,000114,000219,000777,0000
Intangible Assets966,000966,000966,000966,000966,000966,000966,000966,000966,000966,0001,646,0002,326,0003,006,0003,686,000
Investments & Other511,0000000000000000
Debtors (Due After 1 year)00000000000000
Total Fixed Assets2,001,0005,310,0005,596,0006,399,000966,0001,001,0001,065,0001,129,000995,0001,037,0001,760,0002,545,0003,783,0003,686,000
Stock & work in progress54,902,00077,325,00085,162,00058,984,00074,963,00057,043,00056,698,00044,542,00048,963,00037,745,00038,529,00036,667,00044,239,00030,874,000
Trade Debtors32,602,00031,717,00031,342,00033,950,00040,519,00042,946,00042,125,00058,325,00058,425,00045,387,00039,076,00017,646,00014,985,00012,015,000
Group Debtors82,310,00030,723,0002,668,00014,094,00016,513,00030,874,00020,697,00002,030,0002,120,0001,422,0001,523,0004,625,0007,081,000
Misc Debtors468,0001,264,000468,0001,344,0001,914,000703,0001,407,0001,349,0002,001,0002,749,0003,081,0001,941,0001,473,000460,000
Cash00974,00000000000001,730,000
misc current assets00000735,000916,000694,000673,00000000
total current assets170,282,000141,029,000120,614,000108,372,000133,909,000132,301,000121,843,000104,910,000112,092,00088,001,00082,108,00057,777,00065,322,00052,160,000
total assets172,283,000146,339,000126,210,000114,771,000134,875,000133,302,000122,908,000106,039,000113,087,00089,038,00083,868,00060,322,00069,105,00055,846,000
Bank overdraft00000009,990,00034,616,00019,741,00022,552,000922,0007,386,0000
Bank loan00000000000000
Trade Creditors 398,000327,000659,000172,000443,000438,000822,000841,000784,0002,608,000674,0001,421,0002,542,0001,020,000
Group/Directors Accounts68,878,00050,651,00039,406,00032,961,00060,701,00065,173,00059,154,00034,012,00019,804,00023,016,00019,682,00021,445,00026,285,00022,658,000
other short term finances00000000000000
hp & lease commitments00000000000000
other current liabilities26,082,00020,442,00015,840,00014,249,00015,710,00014,722,00014,616,00019,868,00020,736,00012,744,00014,621,00013,546,00012,850,00015,092,000
total current liabilities95,358,00071,420,00055,905,00047,382,00076,854,00080,333,00074,592,00064,711,00075,940,00058,109,00057,529,00037,334,00049,063,00038,770,000
loans00000000000000
hp & lease commitments03,043,0003,583,0003,728,0000000000000
Accruals and Deferred Income00000000000000
other liabilities161,000181,000181,000181,0000000000000
provisions00000000000000
total long term liabilities161,0005,192,0007,471,0007,113,0003,162,0003,170,0004,011,0002,628,0002,584,000752,000689,000692,000713,0001,075,000
total liabilities95,519,00076,612,00063,376,00054,495,00080,016,00083,503,00078,603,00067,339,00078,524,00058,861,00058,218,00038,026,00049,776,00039,845,000
net assets76,764,00069,727,00062,834,00060,276,00054,859,00049,799,00044,305,00038,700,00034,563,00030,177,00025,650,00022,296,00019,329,00016,001,000
total shareholders funds76,764,00069,727,00062,834,00060,276,00054,859,00049,799,00044,305,00038,700,00034,563,00030,177,00025,650,00022,296,00019,329,00016,001,000
Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015Mar 2014Mar 2013Mar 2012Mar 2011Mar 2010
Operating Activities
Operating Profit6,631,0007,904,0005,721,0007,198,0006,481,0006,096,0008,788,0005,939,0006,668,0005,821,0004,967,0004,993,0004,101,0004,771,000
Depreciation615,000832,000881,000546,00035,00064,00064,00059,00042,00043,000105,000558,00054,0003,000
Amortisation00000000680,000680,000680,000680,000680,000680,000
Tax-1,673,000-1,839,000-2,441,000-1,450,000-1,224,000-1,153,000-1,924,000-1,328,000-1,506,000-905,000-1,378,000-1,797,000-868,000-1,925,000
Stock-22,423,000-7,837,00026,178,000-15,979,00017,920,000345,00012,156,000-4,421,00011,218,000-784,0001,862,000-7,572,00013,365,00030,874,000
Debtors51,676,00029,226,000-14,910,000-9,558,000-15,577,00010,294,0004,555,000-2,782,00012,200,0006,677,00022,469,00027,0001,527,00019,556,000
Creditors71,000-332,000487,000-271,0005,000-384,000-19,00057,000-1,824,0001,934,000-747,000-1,121,0001,522,0001,020,000
Accruals and Deferred Income5,640,0004,602,0001,591,000-1,461,000988,000106,000-5,252,000-868,0007,992,000-1,877,0001,075,000696,000-2,242,00015,092,000
Deferred Taxes & Provisions00000000000000
Cash flow from operations-17,969,000-10,222,000-5,029,00030,099,0003,942,000-5,910,000-15,054,00011,062,000-11,366,000-197,000-19,629,00011,554,000-11,645,000-30,789,000
Investing Activities
capital expenditure3,205,000-546,000-78,000-5,979,000000-193,000-680,000000-831,000-4,369,000
Change in Investments511,0000000000000000
cash flow from investments2,694,000-546,000-78,000-5,979,000000-193,000-680,000000-831,000-4,369,000
Financing Activities
Bank loans00000000000000
Group/Directors Accounts18,227,00011,245,0006,445,000-27,740,000-4,472,0006,019,00025,142,00014,208,000-3,212,0003,334,000-1,763,000-4,840,0003,627,00022,658,000
Other Short Term Loans 00000000000000
Long term loans00000000000000
Hire Purchase and Lease Commitments-3,043,000-540,000-145,0003,728,0000000000000
other long term liabilities-20,00000181,0000000000000
share issue1,367,000901,000-577,000-241,000-27,000615,000-1,180,000-112,000-553,000-137,000-92,000-45,000269,00013,247,000
interest756,0000-22,000-90,000-170,000-403,00011,000-279,000-179,000-209,000-96,000-184,000-174,000-92,000
cash flow from financing17,287,00011,606,0005,701,000-24,162,000-4,669,0006,231,00023,973,00013,817,000-3,944,0002,988,000-1,951,000-5,069,0003,722,00035,813,000
cash and cash equivalents
cash0-974,000974,000000000000-1,730,0001,730,000
overdraft000000-9,990,000-24,626,00014,875,000-2,811,00021,630,000-6,464,0007,386,0000
change in cash0-974,000974,0000009,990,00024,626,000-14,875,0002,811,000-21,630,0006,464,000-9,116,0001,730,000

P&L

March 2023

turnover

172.5m

-2%

operating profit

6.6m

-16%

gross margin

5%

-25.31%

turnover

Turnover, or revenue, is the amount of sales generated by a company within the financial year.

Balance Sheet

March 2023

net assets

76.8m

+0.1%

total assets

172.3m

+0.18%

cash

0

0%

net assets

Total assets minus all liabilities

astellas pharma ltd. company details

company number

00787610

Type

Private limited with Share Capital

industry

46460 - Wholesale of pharmaceutical goods

incorporation date

January 1964

age

60

accounts

Full Accounts

ultimate parent company

ASTELLAS PHARMA INC

previous names

yamanouchi pharma ltd. (August 2005)

brocades (great britain) limited (March 1994)

incorporated

UK

address

300 dashwood lang road, bourne business park, addlestone, KT15 2NX

last accounts submitted

March 2023

astellas pharma ltd. Charges & Mortgages

A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.

We did not find charges/mortgages relating to astellas pharma ltd..

charges

astellas pharma ltd. Companies House Filings - See Documents

datedescriptionview/download